Veralox Therapeutics
Ms. Beck has over 25 years of experience in both emerging biotechnology companies and large pharma/biotech. She joined Veralox in 2022 bringing expertise in business development, corporate strategy and development, portfolio management and alliance management. Prior to joining Veralox, Ms. Beck was Senior Vice President of Business Development and Portfolio Management at Brii Biosciences, Executive Director of Business Development and Alliance Management at Alexion Pharmaceuticals, and Senior Director/Director of Business Development and Portfolio Management at GlaxoSmithKline. She has assessed, negotiated and closed over 100 significant business development transactions in her career. She received a B.S. in Biology from Vanderbilt University.
This person is not in any teams
This person is not in any offices
Veralox Therapeutics
Veralox Therapeutics is a biotechnology company developing first-in-class small molecule therapeutics that treat the underlying pathologies of diseases with significant unmet medical needs.